Meningococcal group B vaccines

Jamie Findlow*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Meningococcal disease remains a devastating and feared infection with a significant morbidity and mortality profile. The successful impact of meningococcal capsular group C glyconconjugate vaccines introduced into the UK infant immunization schedule in 1999, has resulted in > 80% of disease now being attributable to meningococcal capsular group B (MenB). MenB glyconconjugate vaccines are not immunogenic and hence, vaccine design has focused on sub-capsular antigens. Recently, a four component vaccine to combat MenB disease (4CMenB) has progressed through clinical development and was approved by the European Medicines Agency at the end of 2012. This vaccine has proven safe and immunogenic and has been predicted to provide protection against ∼ 73% of the MenB disease from England and Wales. Recommendation/ implementation of the vaccine into the UK infant schedule is currently being evaluated. 4CMenB has the potential to provide protection against a significant proportion of MenB disease in the UK which is currently unpreventable.

Original languageEnglish
Pages (from-to)1387-1388
Number of pages2
JournalHuman Vaccines and Immunotherapeutics
Issue number6
Publication statusPublished - Jun 2013


  • Meningococcal disease
  • Meningococcal group B
  • Vaccine


Dive into the research topics of 'Meningococcal group B vaccines'. Together they form a unique fingerprint.

Cite this